B
Benjamin Ortiz
Researcher at Novartis
Publications - 85
Citations - 1317
Benjamin Ortiz is an academic researcher from Novartis. The author has contributed to research in topics: Asthma & Omalizumab. The author has an hindex of 17, co-authored 60 publications receiving 951 citations. Previous affiliations of Benjamin Ortiz include Harlem Hospital Center & Columbia University.
Papers
More filters
Journal ArticleDOI
Addressing the Childhood Asthma Crisis in Harlem: The Harlem Children’s Zone Asthma Initiative
Stephen W. Nicholas,Betina Jean-Louis,Benjamin Ortiz,Mary E. Northridge,Katherine Shoemaker,Roger D. Vaughan,Michaela Rome,Geoffrey Canada,Vincent E. Hutchinson +8 more
TL;DR: The high prevalence of asthma among children in the Harlem Children's Zone Project is consistent with reports from other poor urban communities and intensive efforts are under way to reduce children's asthma symptoms and improve their asthma management strategies.
Journal ArticleDOI
Omalizumab in children with uncontrolled allergic asthma: Review of clinical trial and real-world experience.
Bradley E. Chipps,Bob Lanier,Henry Milgrom,Antoine Deschildre,Gunilla Hedlin,Stanley J. Szefler,Meyer Kattan,Farid Kianifard,Benjamin Ortiz,Tmirah Haselkorn,Ahmar Iqbal,Karin Rosén,Benjamin Trzaskoma,William W. Busse +13 more
TL;DR: The clinical efficacy, safety, and tolerability of omalizumab have been demonstrated in several published clinical trials, which supported the approval of the pediatric indication by the European Medicines Agency and the US Food and Drug Administration in 2009 and 2016, respectively.
Journal ArticleDOI
The national cost of asthma among school-aged children in the United States.
Patrick W. Sullivan,Vahram Ghushchyan,Vahram Ghushchyan,Prakash Navaratnam,Howard S. Friedman,Abhishek Kavati,Benjamin Ortiz,Bob Lanier +7 more
TL;DR: In this paper, a cross-sectional retrospective analysis of school-aged children (aged 6-17 years) in the nationally representative 2007-2013 Medical Expenditure Panel Survey was conducted to estimate the national health care resource use and health care expenditure (HCE) burden associated with adult asthma.
Journal ArticleDOI
Benefits and Harms of Omalizumab Treatment in Adolescent and Adult Patients With Chronic Idiopathic (Spontaneous) Urticaria: A Meta-analysis of “Real-world” Evidence
Michael D. Tharp,Jonathan A. Bernstein,Abhishek Kavati,Benjamin Ortiz,Karen MacDonald,Kris Denhaerynck,Ivo Abraham,Christopher S. Lee +7 more
TL;DR: Benefits and safety of omalizumab in the real-world treatment of CIU meet or exceed results gleaned from clinical trials and may help inform both clinical treatment expectations and policy decision making.
Journal ArticleDOI
More than a decade follow-up in patients with severe or difficult-to-treat asthma: The Epidemiology and Natural History of Asthma: Outcomes and Treatment Regimens (TENOR) II
Bradley E. Chipps,Tmirah Haselkorn,Brandee Paknis,Benjamin Ortiz,Eugene R. Bleecker,Farid Kianifard,Aimee J. Foreman,Stanley J. Szefler,Robert S. Zeiger +8 more
TL;DR: TENOR II provides longitudinal data to characterize disease progression, heterogeneity, and severity in patients with severe or difficult‐to‐treat asthma, including continued morbidity, including a high degree of comorbid conditions, allergic sensitization, exacerbations, and very poorly controlled asthma.